Impact of the Mediterranean Diet on patients with CADASIL and Cerebral Amyloid Angiopathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the nutritional status and dietary habits of patients diagnosed with CADASIL and Cerebral Amyloid Angiopathy (CAA). It consists of two phases: the first phase evaluates adherence to the Mediterranean Diet and its relationship with stroke onset and cognitive decline, while the second phase involves an interventional dietary approach to further analyze the effects of the Mediterranean Diet. The study will measure various parameters, including lean and fat mass, basal metabolism, and total energy expenditure, to understand the potential benefits of dietary changes on these conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The study will include individuals of both sexes aged 18 years or older with a diagnosis of CADASIL (confirmed genetically by the presence of the NOTCH3 gene mutation) or possible/probable CAA (defined according to the Boston 2.0 criteria). All participants must provide informed consent for the use of demographic, clinical, and nutritional data for scientific purposes in an anonymous form

Exclusion Criteria:

* na

Where it's running

• Fondazione IRCCS Istituto Neurologico Carlo Besta
  Milan, Italy Recruiting

Study contacts

• Study coordinator: Anna Bersano, MD
• Email: anna.bersano@istituto-besta.it
• Phone: 02 2394.3062

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding the prognosis of cerebral small vessel disease

  This study looks at how different types of cerebral small vessel disease affect the health and future outcomes of patients, including issues like bleeding in the brain and memory problems.

  Recruiting Insel Gruppe AG, University Hospital Bern · Bern · NCT05734378

• Jiedu Huayu oral medicine for brain hemorrhage due to cerebral amyloid angiopathy

  This trial tests a traditional Chinese medicine oral prescription against placebo to see if it can reduce recurrent vascular events in patients with cerebral amyloid angiopathy-related intracerebral hemorrhage.

  Recruiting Phase 3 Beijing Tiantan Hospital · Beijing · NCT07250035

• Colchicine to prevent repeat lobar brain bleeds from cerebral amyloid angiopathy

  This trial will test whether taking a daily low-dose colchicine pill for a year is safe and helps prevent repeat lobar intracerebral hemorrhage in people with cerebral amyloid angiopathy who are at high risk of another bleed.

  Recruiting Phase 2 Huashan Hospital · Beijing and 2 other locations · NCT07026994

• Using a digital twin app to support people in secondary prevention after stroke, Moyamoya disease, or cerebral amyloid angiopathy

  This trial will try the STRATIF-AI app plus usual secondary prevention care to see if it improves daily self-care and the patient experience for adults after stroke, Moyamoya disease, or CAA.

  Recruiting Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Milan, Michigan · NCT06714097

• Evaluating AMDX-2011P for treating cerebral amyloid angiopathy

  This study is testing a new drug called AMDX-2011P to see if it is safe and effective for people with cerebral amyloid angiopathy.

  Recruiting Phase 2 Amydis Inc. · Phoenix, Arizona · NCT05709314

• Identifying biomarkers for cerebral amyloid angiopathy

  This study is trying to find signs that show how cerebral amyloid angiopathy affects older people, to help doctors better understand and treat the condition.

  Recruiting Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Milan, Milano · NCT04204642

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.